Sunday, May 5, 2024
5/5/2024
PROJECT SUMMARY/ABSTRACT Histone deacetylases (HAT) are zinc-dependent enzymes that catalyze the removal of acetyl groups from the epsilon amine of lysine side chains. These proteins have been widely pursued as anti-cancer drug targets, but therapeutic development has been largely unsuccessful given the essential nature of many HDAC proteins. Recently, we discovered a synthetic lethal relationship between HDAC1 and HDAC2, which is caused by recurrent chromosomal deletions that result in hemizygous deletion of HDAC1 in neuroblastoma and HDAC2 in multiple myeloma. As a result of HDAC1 deletion, neuroblastoma cells are hypersensitive to disruption of HDAC2, and vice versa in multiple myeloma. Using dTAG-mediated degradation or CRISPR/Cas9-based gene disruption, we discovered that targeting HDAC1/2 synthetic lethality (e.g. degrading HDAC2 in neuroblastoma cells with a hemizygous HDAC1 deletion) results in dissociation of the NuRD chromatin remodeler complex, of which HDAC1/2 are members. Dissociation of the complex results in degradation of NuRD subunits that are selectively required for neuroblastoma and multiple myeloma survival, suggesting that HDAC1/2 synthetic lethality can be leveraged to target subunit-specific NuRD vulnerabilities in cancer. We hypothesize that HDAC1 deletions cause the NuRD subunits, HDAC2 / MBD3 / MTA3, to be essential for neuroblastoma, whereas HDAC2 deletions cause vulnerabilities to loss of their paralogs, HDAC1 / MBD2 / MTA2, in multiple myeloma. Here, we will address this hypothesis and explore the translational potential of these vulnerabilities by developing small- molecule modulators that target NuRD structure and/or function. In Aim 1, we will (i) Determine whether MBD and MTA vulnerabilities are caused by HDAC1/2 deletions using CRISPR/Cas9, inducible RNAi, and dTAG- based approaches in vitro and in vivo, (ii) Reveal whether the loss of NuRD subunits required for cancer cell survival leads to dissociation and/or degradation of the NuRD complex using unbiased proteomics approaches, and (iii) Establish if HDAC1/MBD2/MTA2 and HDAC2/MBD3/MTA3 form distinct NuRD sub-complexes as a result of HDAC2 and HDAC1 deletions, respectively. These experiments will determine if subunit-specific NuRD vulnerabilities are caused by HDAC1/2 deletions or simply exploited by HDAC1/2 synthetic lethality. In Aim 2, we will develop small molecules targeting the NuRD complex to exploit NuRD vulnerabilities in genetically defined cancer sub-types. Specifically, we will: (i) develop paralog-selective PROTACs that distinguish between HDAC1 and HDAC2, (ii) determine the potential for covalent ligands of MTA3-Cys532 to disrupt NuRD structure and/or function in MTA3-dependent cancers, and (iii) develop MTA3-targeted PROTACs based on ligands that covalently engage MTA3-C532. Altogether, successful completion of these aims will determine the mechanisms underlying NuRD vulnerabilities in cancer and advance novel chemical tools to drug and study them.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
